IPCA Labs shares: Unichem acquisition expensive, earnings dilutive in near term, says Motilal Oswal Securities
IPCA Labs: Motilal Oswal Securities said the acquisition is expensive, given increased competition in the US generics oral solids space, rising regulatory risks, strong efforts needed to turnaround Unichem,